SAN FRANCISCO, January 7, 2021, Shasqi, a clinical stage biotechnology company whose mission is to enable patients to beat cancer without poisoning their bodies, announced today that Founder & Chief Executive Officer José M. Mejía Oneto, MD, PhD, will present at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday January 13th at 2:00pm Eastern Time.

Dr. Mejia Oneto’s presentation will be available as a live webcast through the JP Morgan conference portal and an archived recording will be made available after the conference. For those not registered for the conference, there is a public access available to listen in via audio and follow along with the slides presented here

Shasqi is currently advancing its lead clinical candidate, SQ3370, a click-activated protodrug therapy, in a phase 1 clinical trial. SQ3370 is the first click chemistry-based treatment to be tested in humans. That study, SQ3370-001, is currently enrolling patients with advanced sarcomas and other solid tumors in the United States and Australia (ClinicalTrials.gov Identifier NCT04106492). The company presented pre-clinical and trial-in-progress data from the SQ3370 program in late 2020. Those presentations are available on www.shasqi.com.